0 CHECKOUT

Hereditary Angioedema (HAE) - Pipeline Review, H1 2015

  • ID: 3293084
  • May 2015
  • 78 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • CSL Limited
  • Dyax Corp.
  • iBio, Inc.
  • Pharming Group N.V.
  • Ra Pharmaceuticals, Inc.
  • Shire Plc
  • MORE

Hereditary Angioedema (HAE) - Pipeline Review, H1 2015

Summary

This, ‘Hereditary Angioedema (HAE) - Pipeline Review, H1 2015’, provides an overview of the Hereditary Angioedema (HAE)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • CSL Limited
  • Dyax Corp.
  • iBio, Inc.
  • Pharming Group N.V.
  • Ra Pharmaceuticals, Inc.
  • Shire Plc
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Hereditary Angioedema (HAE) Overview
Therapeutics Development
Pipeline Products for Hereditary Angioedema (HAE) - Overview
Pipeline Products for Hereditary Angioedema (HAE) - Comparative Analysis
Hereditary Angioedema (HAE) - Therapeutics under Development by Companies
Hereditary Angioedema (HAE) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Hereditary Angioedema (HAE) - Products under Development by Companies
Hereditary Angioedema (HAE) - Companies Involved in Therapeutics Development
BioCryst Pharmaceuticals, Inc.
Cevec Pharmaceuticals GmbH
CSL Limited
Dyax Corp.
Global Blood Therapeutics, Inc.
iBio, Inc.
Isis Pharmaceuticals, Inc.
Pharming Group N.V.
Ra Pharmaceuticals, Inc.
Shire Plc
Hereditary Angioedema (HAE) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BCX-4161 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BCX-7353 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BEL-0215 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CSL-312 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DX-2930 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
icatibant acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISIS-PKKRx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule 2 to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Hereditary Angioedema - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide to Inhibit Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hereditary Angioedema (HAE) - Recent Pipeline Updates
Hereditary Angioedema (HAE) - Dormant Projects
Hereditary Angioedema (HAE) - Dormant Projects
Hereditary Angioedema (HAE) - Product Development Milestones
Featured News & Press Releases
Apr 09, 2015: Dyax to Participate in the 14th Annual Needham Healthcare Conference
Mar 31, 2015: Dyax Announces Positive Results from Phase 1b Clinical Trial of DX-2930
Feb 24, 2015: ISIS Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions in Prekallikrein Levels
Feb 02, 2015: CEVEC: CAP Derived Recombinant C1 Inhibitor Matches Berinert in Animal Study
Jan 08, 2015: Pharming and Salix Announce First Patient Treated in Clinical Study of Ruconest for Prophylaxis of Hereditary Angioedema
Dec 18, 2014: Dyax First-in-Human Trial for DX-2930 Conducted by Vince and Associates Clinical Research Featured in the Annals of Allergy, Asthma & Immunology
Nov 04, 2014: Pharming Confirms Receipt Of US$20 Million Milestone Payment From Salix Pharmaceuticals
Nov 03, 2014: Salix and Pharming Announce the Launch of RUCONEST in the U.S. for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
Nov 03, 2014: Dyax Announces Expansion of Phase 1b Clinical Trial for DX-2930
Oct 13, 2014: Pharming and Swedish Orphan Biovitrum Amend and Extend Ruconest Distribution Agreement
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hereditary Angioedema (HAE), H1 2015
Number of Products under Development for Hereditary Angioedema (HAE) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Hereditary Angioedema (HAE) - Pipeline by BioCryst Pharmaceuticals, Inc., H1 2015
Hereditary Angioedema (HAE) - Pipeline by Cevec Pharmaceuticals GmbH, H1 2015
Hereditary Angioedema (HAE) - Pipeline by CSL Limited, H1 2015
Hereditary Angioedema (HAE) - Pipeline by Dyax Corp., H1 2015
Hereditary Angioedema (HAE) - Pipeline by Global Blood Therapeutics, Inc., H1 2015
Hereditary Angioedema (HAE) - Pipeline by iBio, Inc., H1 2015
Hereditary Angioedema (HAE) - Pipeline by Isis Pharmaceuticals, Inc., H1 2015
Hereditary Angioedema (HAE) - Pipeline by Pharming Group N.V., H1 2015
Hereditary Angioedema (HAE) - Pipeline by Ra Pharmaceuticals, Inc., H1 2015
Hereditary Angioedema (HAE) - Pipeline by Shire Plc, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Hereditary Angioedema (HAE) Therapeutics - Recent Pipeline Updates, H1 2015
Hereditary Angioedema (HAE) - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Hereditary Angioedema (HAE), H1 2015
Number of Products under Development for Hereditary Angioedema (HAE) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

BioCryst Pharmaceuticals, Inc.
Cevec Pharmaceuticals GmbH
CSL Limited
Dyax Corp.
Global Blood Therapeutics, Inc.
iBio, Inc.
Isis Pharmaceuticals, Inc.
Pharming Group N.V.
Ra Pharmaceuticals, Inc.
Shire Plc

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Merck & Co., Inc.
  • Celgene Corporation
  • GlaxoSmithKline PLC
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc.
  • ViiV Healthcare